US3444858A - Method and means for administering drugs - Google Patents

Method and means for administering drugs Download PDF

Info

Publication number
US3444858A
US3444858A US549381A US3444858DA US3444858A US 3444858 A US3444858 A US 3444858A US 549381 A US549381 A US 549381A US 3444858D A US3444858D A US 3444858DA US 3444858 A US3444858 A US 3444858A
Authority
US
United States
Prior art keywords
vehicle
strip
drug
gum
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US549381A
Inventor
Higham S Russell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HIGHAM S RUSSELL
Original Assignee
HIGHAM S RUSSELL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HIGHAM S RUSSELL filed Critical HIGHAM S RUSSELL
Application granted granted Critical
Publication of US3444858A publication Critical patent/US3444858A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0092Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine for holding medicines in, or fixing medicines on, a tooth, e.g. holder containing medicines fixed on a tooth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00Devices for applying media, e.g. remedies, on the human body
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S206/00Special receptacle or package
    • Y10S206/82Separable, striplike plural articles

Definitions

  • a vehicle for administering a drug comprising an elongate sectionalized strip of resiliently flexible gelatinous material of a section which enables a length thereof conveniently to be inserted into the buccal sulcus so as to adhere to the gum thereat, the vehicle containing a drug having a capacity to be absorbed through the users buccal mucous membrane, the strip being so formed at intervals therealong as to facilitate its being subdivided to provide individual sections of a desired drug dosage.
  • This invention concerns a vehicle for administering drugs.
  • drugs should desirably be administered gradually and progressively only until a desired effect is obtained, and this is difiicult to carry out with the means hitherto available.
  • An object of the invention is to provide a vehicle for administering drugs whereby the aforementioned difliculties are minimised, the vehicle providing for a particularly convenient, simple and accurate method of administration.
  • a vehicle for administering drugs comprising an elongate strip of resiliently flexible gelatinous material of a section which enables a length thereof conveniently to be inserted in the buccal sulcus so as to adhere to the gum thereat, the vehicle containing a drug (preferably of a type which, if swallowed, would be destroyed or inactivated by saliva or fluids in the stomach, or would produce undesired side effects, or would require to be administered in massive overdoses), which is effective when absorbed through the buccal mucous membrane of a person, the said strip being marked or otherwise formed at intervals therealong to facilitate it being divided up to provide individual lengths of desired drug content or dosage.
  • a drug preferably of a type which, if swallowed, would be destroyed or inactivated by saliva or fluids in the stomach, or would produce undesired side effects, or would require to be administered in massive overdoses
  • the invention also provides a method of making a vehicle as aforesaid comprising the steps of preparing a liquid solution or melt of a gelatinous material, impregnating the solution or melt with the said drug and forming the impregnated solution or melt into the vehicle.
  • the vehicle is preferably of a form of glyco-gelatine 3,444,858 Patented May 20, 1969 which is sufliciently firm and solid to be resilient, and is conveniently in the form of an extrusion of rectangular or oval cross section.
  • the vehicle is impregnated with a drug of very potent nature as such drugs are usually effective even when administered in very small amounts eg in doses of a fraction of a milligram.
  • FIG. 1 is an enlarged perspective view showing part of a first embodiment of the vehicle of the invention
  • FIG. 2 is a section corresponding to the line IIII of FIG. 1;
  • FIGS. 3, 4, 5, 6 and 7 are views similar to FIG. 2 but showing five suitable alternative cross-sections for the vehicle;
  • FIGS. 8 and 9 are views similar to FIG. 1 but showing two further embodiments of the vehicle
  • FIG. 10 is a diagrammatic view showing a small length of the vehicle of FIGS. 1 and 2 in its position of use.
  • FIG. 11 is a view similar to FIG. 10 but showing a longer length of the vehicle in use.
  • a vehicle for administering drugs in conformity with the invention comprises an elongate strip 10, generally of rectangular crosssection and made of a resilient flexible gelatinous material such as glyco-gelatine. Contained in such material is a drug the nature of which will be discussed later.
  • the strip 10 is formed at intervals therealong with pairs of transverse depressions 11 in opposite major faces thereof so as to divide the strip into a plurality of sections '12 which are each connected to the next adjacent sections by comparatively weak ligaments 13.
  • ligaments 13 The purpose of these ligaments 13 is to enable the strip 10 to be torn or otherwise divided up into individual lengths each of which consists of one or a desired number of the sections 12.
  • FIG. 10 shows how the vehicle of FIGS. 1 and 2 may be used.
  • a single section 12 after having been severed from the strip 10, is inserted into the buccal sulcus 14 at the front of a patients mouth and is pressed firmly against the gum 15 thereat.
  • the material of the section 12 is flexible and resilient and the gum is usually slightly moist with saliva, the section 12 can be pressed to the gum 15 so as to substantially immediately adhere to the gum 15 at the upper part thereof, to occupy substantially wholly the upper part of the space defined by the transition between the gum 15 and the adjacent lip 16.
  • the section 12 immedi ately excludes saliva from that part of the gum 15 which it overlies, and access thereto of saliva from the rest of the mouth is minimised by the lip 16.
  • the material At the face of the material abutting the gum 15, such material slowly goes into solution and is absorbed into the patients bloodstream through the gum 15, gradual dissolution of the material ensuring that there is a constant supply thereof available for absorption.
  • each section 12 thereof contains a predetermined quantity of the drug
  • a desired dosage of the drug can be administered by the use of an appropriate number of the sections 12.
  • FIG. 10 shows a single section 12 in position for administration, a plurality thereof can be administered simultaneously as shown in FIG. 11, each of the sections 12 adhering to the gum 15 for absorption therethrough.
  • the vehicle 10 can be of any cross-section which is suitable for insertion into the buccal sulcus at the front of the users mouth and which will readily adhere to the gum thereat.
  • it may be square in cross-section as is the case of the vehicle 10a of FIG. 3, it may be cir- 3 cular (vehicle 10b of FIG. 4), oval (vehicle 100 of FIG. 5), of thin strip form with its two major faces 17 and 18 respectively convex and concave (vehicle d of FIG.
  • the ligaments 13 are shown as having been defined by pairs of depressions 11 extending inwards from the opposite edges of the vehicle instead of from the opposite major faces 17, 18 and 19, 20.
  • these vehicles can be formed with depressions 11 similar to those of FIGS. 1 to 5 and conversely the vehicles of FIGS. 1 to 5 may have depressions similar to those of FIGS. 6 and 7.
  • a vehicle 10 comparable to those of FIGS. 6 and 7 is shown in FIG. 8, the vehicle here being substantially flat strip form to provide fiat sections 12.
  • pairs of depressions 11 are provided at intervals along the strip, but it will be appreciated that the strip can equally well be divided or graduated into sections, preferably of equal sizes, by single depressions at intervals along the strip such depressions extending from edge to edge or from side to side of the strip, whereby the strip may readily be torn across, or extending only part of the way across the strip simply by way of graduations defining the individual sections 12 and providing appropriate indications for cutting the strip as desired, e.g. by use of scissors.
  • the strip can be marked or graduated by means of thickened ribs instead of depressions.
  • Such a vehicle is illustrated at 10g in FIG. 9 wherein the vehicle is graduated in section 12 by ribs 21 extending from edge to edge of the strip on one face only thereof. These ribs 21 can, of course, extend only part of the way across the strip.
  • the vehicles as described can be made in any suitable manner whereby glyco-gelatine may be formed into strips, and the following exemplifies one way in which it may be carried out.
  • the desired drug is stirred, mixed or otherwise thoroughly dispersed into a batch of glyco-gelatine solution or melt, and such material is then run into a series of moulds each of which is shaped according to the desired strip from of the vehicle, the glyco-gelatine, with the drug contained therein, being hardened and dried whilst in the moulds to such a degree that the strips, upon being stripped from the moulds can conveniently be handled yet are resilient and flexible.
  • the material containing the drug may be appropriately extended in continuous strip form, the graduations, depressions, ribs or other markings being subsequently produced thereon, for example by passing the strip through a nip formed by a paid of heated rollers shaped to form the depressions thereon.
  • glyco-gel'atine based mixtures, or a gelatinous material based on the alginates, or other suitable (e.g. resin-based) material may be used, but a material based on glyco-gelatine is preferred.
  • the material of the above described example will have a melting point near blood heat e.g. between 105 and F. and is soft and resiliently pliable at the temperature usual in the mouth. Furthermore, the material is virtually non-toxic and has no side effects on the patient; it is soluble in water, is almost tasteless, and is thus suitable for absorption through the mucous membrane of the gum, i.e. in the buccal sulcus. These properties or proportions similar thereto are necessary for any alternative material.
  • the drug incorporated in the vehicle of the invention will be present in a small quantity e.g. a few microgrammes or milligrammes of the drug per centimetre length of the vehicle.
  • the drug may be of various types such as those which are usually injected or given rectally because they are:
  • Type 1.-Hormones such as the steroid hormones; and the polypeptide hormones e.g. vasopressin and insulin. Further examples are: oxytocin; testosterone; oestrogens, and progesterones.
  • Type 2.--Loca-l anaesthetics and the like e.g., ligno caine hydrochloride and diperodon hydrochloride.
  • Type 3.Sympathomimet-ic amines e.g., adrenaline, noradrenaline, isprenaline and amphetamine, and substances which have an opposing action such as ergotamine and dibenilene.
  • Type 4.--Substances to be given when a prompt response may be desirable, e.g. vasco-dilators; quick acting diuretics; analgesics e.g. morphine; and cardiovascular reactants e.g. glyceryl trinitrate.
  • Type 5 Substances having an optimum dose not ascertainable before administration, e.g. oxytocin, digitalin, barbiturates, muscle relaxants and ganglion blocking agents.
  • Type 6. Substances acting on the parasympathetic system, e.g. acetylcholine, anticholinesterases and physestigmine.
  • Type 7 Various other substances which are potent when absorbed, such as antihistamines, e.g. promethazine; alkaloids, and glycosides such as atropine and hyoscine; nitrates e.g. amyl nitrate; analeptics e.g. caffine and amphetamines; cytoatoxic agents; anticoagulants e.g. heparin; vitamins such as cyanocobalamin; and trace element substances.
  • antihistamines e.g. promethazine
  • alkaloids e.g. amyl nitrate
  • analeptics e.g. caffine and amphetamines
  • cytoatoxic agents e.g. heparin
  • vitamins such as cyanocobalamin
  • trace element substances such as antihistamines, e.g. promethazine; alkaloids, and glycosides such as atropine and hyoscine
  • nitrates
  • Type 8.Metabolic reactants for clincal investigations e.g. para-amino-hippuric acid.
  • an appropriate length of the vehicle is severed from the strip and the severed length is inserted into the buccal su'lcus as described. It is thereafter entirely absorbed into the gum or is allowed to be absorbed until the desired effect is obtained.
  • the vehicle does not fragment and therefore may be easily removed when suflicient of the drug has been absorbed, and the cut length will be readily retained in the sulcus due to its semi-plastic nature. Since the severed length of the vehicle is entirely contained within the buccal sulcus little or none of the drug need be Washed away or inactivated by saliva, and since the vehicle is hardly felt when in place it does not provoke salivation. Furthermore, the vehicle is located away from the flow path of any saliva which may be secreted.
  • the length of the vehicle, being severed from a strip, may be chosen so as to facilitate the administration of an exact and chosen amount ofthe drug.
  • the patient can talk, eat, smoke, drink and cough without any fear of ingesting or swallowing the vehicle.
  • the vehicles are impregnated with oxytocin, a drug which is used to induce labour in pregnancy.
  • oxytocin is usually administered as an intravenous drip which is extremely inconvenient during the wait for labour to begin.
  • the vehicle obviates the need for an intravenous drip, and can be removed as soon as the required degree of muscular contractions are evident. Thus the risk of rupturing the uterus may be substantially reduced. In this case should the vehicle be swallowed the drug will become inactivated by the stomach and no damage will advertently ensue.
  • the vehicle also obviates some disadvantages which are inherent in compressed pulverulent tablets, e.g.
  • the vehicle may contain a smaller dosage than a comparable tablet and yet be just as effective. Furthermore, the vehicle is absorbed in a more regular manner and absorption peaks, and the corresponding over reactions by the patient, are avoided.
  • Type 2 substances i.e. local anaesthetics
  • the vehicle for such use may also include antibiotics and haemostatic substances, the vehicle being superimposed upon the gum adjacent the tooth to be treated or removed, to deaden the pain of injections and the subsequent operations.
  • an absorbable preparation may be incorporated into vehicles and administered by the method of this invention, which is particularly suitable for the administration of drugs which vary in potency according to the condition of the patient, as the vehicle may be removed when sufficient of the drug has been absorbed.
  • the vehicle may be prepared by any suitable means and from any suitable flexible or gelatinous material, and, in the stance wherein the material comprises mainly glyco-gelatine, various plasticisors and diluents may be incorporated, not only to improve and/ or vary the qualities of the vehicle, but also to facilitate the production thereof, and the incorporation of the drug or drugs thereinto.
  • the vehicle may be formed, provided with a protective coating and marker linearly in a continuous operation.
  • the vehicle may have any suitable cross-section but the cross-section should be of a size and shape commensurate with the size of the buccal sulcus of an average person. It is possible also to form smaller dimensioned vehicles suitable for treating children.
  • Any coating provided on the vehicle may be of a type which must be removed before use, or a saliva soluble coating may be used, the vehicle being moistened with saliva before insertion into the buccal sulcus. It is also possible to embody in the vehicle a drug suitable for administration to animals.
  • a vehicle for administering a drug comprising: an elongate sectionalized strip for resiliently flexible gelatinous material enabling a desired length thereof conveniently to be inserted into the buccal sulcus for adherence to the gum thereat and containing a drug absorbable through a users buccal mucous membrane, the said strip being formed at intervals therealong to facilitate it being subdivided for providing individual sections of a desired drug dosage, with the strip being formed at intervals therealong with depressions extending transversely of the strip and dividing the latter into a plurality of sections each being connected to the next adjacent sections by readily tearable ligaments.
  • a vehicle as claimed in claim 1 wherein the strip is of oval or circular cross-section.

Description

y 1969 H. s. RUSSELL 3,444,858
METHOD AND MEANS FOR ADMINISTERING DRUGS Filed May 11. 1966 MFA/7'0? HGHAM STANLEY RUSS L ATTORNEY.
United States Patent 3,444,858 METHOD AND MEANS FOR ADMINISTERING DRUGS Higham S. Russell, 29 Camberley Drive, Rochdale, Lancashire, England Filed May 11, 1966, Ser. No. 549,381 Claims priority, application Great Britain, May 14, 1965, 20,377/ 65 Int. Cl. A61m 31/00; A6113 7/02; A611 15/00 US. Cl. 128260 Claims ABSTRACT OF THE DISCLOSURE A vehicle for administering a drug comprising an elongate sectionalized strip of resiliently flexible gelatinous material of a section which enables a length thereof conveniently to be inserted into the buccal sulcus so as to adhere to the gum thereat, the vehicle containing a drug having a capacity to be absorbed through the users buccal mucous membrane, the strip being so formed at intervals therealong as to facilitate its being subdivided to provide individual sections of a desired drug dosage.
This invention concerns a vehicle for administering drugs.
It is well known that various drugs, be they hormonal preparations or otherwise, are destroyed or inactivated by saliva in the mouth or fluids in the stomach if they are administeredfby way of the digestive tract, and certain drugs mayhave undesirable side effects when ad ministered orally. Therefore, such drugs are, where possible, injected into the body, but this procedure is not very convenient to adopt in many circumstances, there being well known risks in the giving of injections.
Other drugs capable of being administered orally are only very slightly absorbed into the body through the stomach. In these cases, massive overdoses have to be administered, and this, too, is not very satisfactory as the rate of absorption varies considerably from patient to patient and accurate forecast of optimum dosage cannot be made.
In certain instances drugs should desirably be administered gradually and progressively only until a desired effect is obtained, and this is difiicult to carry out with the means hitherto available.
An object of the invention is to provide a vehicle for administering drugs whereby the aforementioned difliculties are minimised, the vehicle providing for a particularly convenient, simple and accurate method of administration.
According to the present invention there is provided a vehicle for administering drugs, comprising an elongate strip of resiliently flexible gelatinous material of a section which enables a length thereof conveniently to be inserted in the buccal sulcus so as to adhere to the gum thereat, the vehicle containing a drug (preferably of a type which, if swallowed, would be destroyed or inactivated by saliva or fluids in the stomach, or would produce undesired side effects, or would require to be administered in massive overdoses), which is effective when absorbed through the buccal mucous membrane of a person, the said strip being marked or otherwise formed at intervals therealong to facilitate it being divided up to provide individual lengths of desired drug content or dosage.
The invention also provides a method of making a vehicle as aforesaid comprising the steps of preparing a liquid solution or melt of a gelatinous material, impregnating the solution or melt with the said drug and forming the impregnated solution or melt into the vehicle.
The vehicle is preferably of a form of glyco-gelatine 3,444,858 Patented May 20, 1969 which is sufliciently firm and solid to be resilient, and is conveniently in the form of an extrusion of rectangular or oval cross section.
In a preferred form the vehicle is impregnated with a drug of very potent nature as such drugs are usually effective even when administered in very small amounts eg in doses of a fraction of a milligram.
The invention will be described further, by way of example, with reference to the accompanying drawings, in which:
FIG. 1 is an enlarged perspective view showing part of a first embodiment of the vehicle of the invention;
FIG. 2 is a section corresponding to the line IIII of FIG. 1;
FIGS. 3, 4, 5, 6 and 7 are views similar to FIG. 2 but showing five suitable alternative cross-sections for the vehicle;
FIGS. 8 and 9 are views similar to FIG. 1 but showing two further embodiments of the vehicle;
FIG. 10 is a diagrammatic view showing a small length of the vehicle of FIGS. 1 and 2 in its position of use; and
FIG. 11 is a view similar to FIG. 10 but showing a longer length of the vehicle in use.
Referring firstly to FIGS. 1 and 2, a vehicle for administering drugs in conformity with the invention comprises an elongate strip 10, generally of rectangular crosssection and made of a resilient flexible gelatinous material such as glyco-gelatine. Contained in such material is a drug the nature of which will be discussed later. As can be seen, the strip 10 is formed at intervals therealong with pairs of transverse depressions 11 in opposite major faces thereof so as to divide the strip into a plurality of sections '12 which are each connected to the next adjacent sections by comparatively weak ligaments 13.
The purpose of these ligaments 13 is to enable the strip 10 to be torn or otherwise divided up into individual lengths each of which consists of one or a desired number of the sections 12.
FIG. 10 shows how the vehicle of FIGS. 1 and 2 may be used. A single section 12, after having been severed from the strip 10, is inserted into the buccal sulcus 14 at the front of a patients mouth and is pressed firmly against the gum 15 thereat. Because the material of the section 12 is flexible and resilient and the gum is usually slightly moist with saliva, the section 12 can be pressed to the gum 15 so as to substantially immediately adhere to the gum 15 at the upper part thereof, to occupy substantially wholly the upper part of the space defined by the transition between the gum 15 and the adjacent lip 16. As soon as it adheres in position, the section 12 immedi ately excludes saliva from that part of the gum 15 which it overlies, and access thereto of saliva from the rest of the mouth is minimised by the lip 16. At the face of the material abutting the gum 15, such material slowly goes into solution and is absorbed into the patients bloodstream through the gum 15, gradual dissolution of the material ensuring that there is a constant supply thereof available for absorption.
Assuming the vehicle 10 to have been produced so that each section 12 thereof contains a predetermined quantity of the drug, it will be evident that a desired dosage of the drug can be administered by the use of an appropriate number of the sections 12. Thus, whilst FIG. 10 shows a single section 12 in position for administration, a plurality thereof can be administered simultaneously as shown in FIG. 11, each of the sections 12 adhering to the gum 15 for absorption therethrough.
The vehicle 10 can be of any cross-section which is suitable for insertion into the buccal sulcus at the front of the users mouth and which will readily adhere to the gum thereat. Thus, it may be square in cross-section as is the case of the vehicle 10a of FIG. 3, it may be cir- 3 cular (vehicle 10b of FIG. 4), oval (vehicle 100 of FIG. 5), of thin strip form with its two major faces 17 and 18 respectively convex and concave (vehicle d of FIG.
6) or of thicker strip form with convex and concave faces.
19 and 20* respectively (vehicle Me of FIG. 7). When sections 12 of the latter two vehicles 10d and 10e are used, the concave surfaces 18, 20 are pressed against the gum 15.
In the case of the two vehicles 10d and 10e of FIGS. 6 and 7, the ligaments 13 are shown as having been defined by pairs of depressions 11 extending inwards from the opposite edges of the vehicle instead of from the opposite major faces 17, 18 and 19, 20. Naturally, it will be understood that these vehicles can be formed with depressions 11 similar to those of FIGS. 1 to 5 and conversely the vehicles of FIGS. 1 to 5 may have depressions similar to those of FIGS. 6 and 7. A vehicle 10 comparable to those of FIGS. 6 and 7 is shown in FIG. 8, the vehicle here being substantially flat strip form to provide fiat sections 12.
Elm all the forms of the vehicle so far described and illustrated, pairs of depressions 11 are provided at intervals along the strip, but it will be appreciated that the strip can equally well be divided or graduated into sections, preferably of equal sizes, by single depressions at intervals along the strip such depressions extending from edge to edge or from side to side of the strip, whereby the strip may readily be torn across, or extending only part of the way across the strip simply by way of graduations defining the individual sections 12 and providing appropriate indications for cutting the strip as desired, e.g. by use of scissors. Conversely, the strip can be marked or graduated by means of thickened ribs instead of depressions. Such a vehicle is illustrated at 10g in FIG. 9 wherein the vehicle is graduated in section 12 by ribs 21 extending from edge to edge of the strip on one face only thereof. These ribs 21 can, of course, extend only part of the way across the strip.
The vehicles as described can be made in any suitable manner whereby glyco-gelatine may be formed into strips, and the following exemplifies one way in which it may be carried out.
Firstly the desired drug is stirred, mixed or otherwise thoroughly dispersed into a batch of glyco-gelatine solution or melt, and such material is then run into a series of moulds each of which is shaped according to the desired strip from of the vehicle, the glyco-gelatine, with the drug contained therein, being hardened and dried whilst in the moulds to such a degree that the strips, upon being stripped from the moulds can conveniently be handled yet are resilient and flexible.
Alternatively, the material containing the drug may be appropriately extended in continuous strip form, the graduations, depressions, ribs or other markings being subsequently produced thereon, for example by passing the strip through a nip formed by a paid of heated rollers shaped to form the depressions thereon.
The following is an example of a suitable composition for the gelatinous material:
Percent by weight Gelatine B.P. 45.48 Glycerine B.P. 16.20 Water 38.32
Other glyco-gel'atine"based mixtures, or a gelatinous material based on the alginates, or other suitable (e.g. resin-based) material may be used, but a material based on glyco-gelatine is preferred. The material of the above described example will have a melting point near blood heat e.g. between 105 and F. and is soft and resiliently pliable at the temperature usual in the mouth. Furthermore, the material is virtually non-toxic and has no side effects on the patient; it is soluble in water, is almost tasteless, and is thus suitable for absorption through the mucous membrane of the gum, i.e. in the buccal sulcus. These properties or proportions similar thereto are necessary for any alternative material.
The drug incorporated in the vehicle of the invention will be present in a small quantity e.g. a few microgrammes or milligrammes of the drug per centimetre length of the vehicle. The drug may be of various types such as those which are usually injected or given rectally because they are:
(a) substantially destroyed or inactivated in the stomach or intestines, when ingested;
-(b) active in an unwanted manner upon the stomach or intestines to produce undesirable side effects when ingested;
(c) variable in absorption or eifect from patient to patient;
((1) slow to act when ingested so that they require massive overdoses to be effective; or
(e) of local application.
The principal types of drugs are as follows:
Type 1.-Hormones; their derivatives and analogues, such as the steroid hormones; and the polypeptide hormones e.g. vasopressin and insulin. Further examples are: oxytocin; testosterone; oestrogens, and progesterones.
Type 2.--Loca-l anaesthetics and the like e.g., ligno caine hydrochloride and diperodon hydrochloride.
Type 3.Sympathomimet-ic amines e.g., adrenaline, noradrenaline, isprenaline and amphetamine, and substances which have an opposing action such as ergotamine and dibenilene.
Type 4.--Substances to be given when a prompt response may be desirable, e.g. vasco-dilators; quick acting diuretics; analgesics e.g. morphine; and cardiovascular reactants e.g. glyceryl trinitrate.
Type 5.-Substances having an optimum dose not ascertainable before administration, e.g. oxytocin, digitalin, barbiturates, muscle relaxants and ganglion blocking agents.
Type 6.-Substances acting on the parasympathetic system, e.g. acetylcholine, anticholinesterases and physestigmine.
Type 7.Various other substances which are potent when absorbed, such as antihistamines, e.g. promethazine; alkaloids, and glycosides such as atropine and hyoscine; nitrates e.g. amyl nitrate; analeptics e.g. caffine and amphetamines; cytoatoxic agents; anticoagulants e.g. heparin; vitamins such as cyanocobalamin; and trace element substances.
Type 8.Metabolic reactants for clincal investigations e.g. para-amino-hippuric acid.
It is possible to use any drug which is sufliciently stable, potent, and absorbable. A good example is insulin even though it has a substantial molecular weight.
In use when it is desired to administer a given amount of the drug, an appropriate length of the vehicle is severed from the strip and the severed length is inserted into the buccal su'lcus as described. It is thereafter entirely absorbed into the gum or is allowed to be absorbed until the desired effect is obtained.
Due to the fact that the vehicle is, eflectively, a solution of the drug in a gelatinous material, the rate of absorption is remarkably constant, especially when compared with the absorption rates of a tablet of compressed particulate material having a similar overall concentra= tion of the dr g, but having a par iculate character.
Furthermore, the vehicle does not fragment and therefore may be easily removed when suflicient of the drug has been absorbed, and the cut length will be readily retained in the sulcus due to its semi-plastic nature. Since the severed length of the vehicle is entirely contained within the buccal sulcus little or none of the drug need be Washed away or inactivated by saliva, and since the vehicle is hardly felt when in place it does not provoke salivation. Furthermore, the vehicle is located away from the flow path of any saliva which may be secreted.
The length of the vehicle, being severed from a strip, may be chosen so as to facilitate the administration of an exact and chosen amount ofthe drug.
Due to its adhesive properties and to the fact that the severed lengths of the vehicle tends to adopt the shape of the sulcus after a very short time, the patient can talk, eat, smoke, drink and cough without any fear of ingesting or swallowing the vehicle.
In one particular application and embodiment the vehicles are impregnated with oxytocin, a drug which is used to induce labour in pregnancy. It will be readily appreciated that the vehicle and method described offer a further advantage, in this particular application, in that oxytocin is usually administered as an intravenous drip which is extremely inconvenient during the wait for labour to begin. The vehicle obviates the need for an intravenous drip, and can be removed as soon as the required degree of muscular contractions are evident. Thus the risk of rupturing the uterus may be substantially reduced. In this case should the vehicle be swallowed the drug will become inactivated by the stomach and no damage will advertently ensue. The vehicle also obviates some disadvantages which are inherent in compressed pulverulent tablets, e.g. such tablets are often uncomfortable and make their presence felt in the mouth and thus stimulate salivation, such salivation causing the substance to be washed away and sometimes inactivated. Therefore, the vehicle may contain a smaller dosage than a comparable tablet and yet be just as effective. Furthermore, the vehicle is absorbed in a more regular manner and absorption peaks, and the corresponding over reactions by the patient, are avoided.
Type 2 substances, i.e. local anaesthetics, are particularly suitable for use in dentistry, and the vehicle for such use may also include antibiotics and haemostatic substances, the vehicle being superimposed upon the gum adjacent the tooth to be treated or removed, to deaden the pain of injections and the subsequent operations.
The invention is not confined to the precise details of the foregoing example and many variations are possible.
For instance an absorbable preparation may be incorporated into vehicles and administered by the method of this invention, which is particularly suitable for the administration of drugs which vary in potency according to the condition of the patient, as the vehicle may be removed when sufficient of the drug has been absorbed.
The vehicle may be prepared by any suitable means and from any suitable flexible or gelatinous material, and, in the stance wherein the material comprises mainly glyco-gelatine, various plasticisors and diluents may be incorporated, not only to improve and/ or vary the qualities of the vehicle, but also to facilitate the production thereof, and the incorporation of the drug or drugs thereinto. Also, the vehicle may be formed, provided with a protective coating and marker linearly in a continuous operation. The vehicle may have any suitable cross-section but the cross-section should be of a size and shape commensurate with the size of the buccal sulcus of an average person. It is possible also to form smaller dimensioned vehicles suitable for treating children. Any coating provided on the vehicle may be of a type which must be removed before use, or a saliva soluble coating may be used, the vehicle being moistened with saliva before insertion into the buccal sulcus. It is also possible to embody in the vehicle a drug suitable for administration to animals.
I claim:
1. A vehicle for administering a drug comprising: an elongate sectionalized strip for resiliently flexible gelatinous material enabling a desired length thereof conveniently to be inserted into the buccal sulcus for adherence to the gum thereat and containing a drug absorbable through a users buccal mucous membrane, the said strip being formed at intervals therealong to facilitate it being subdivided for providing individual sections of a desired drug dosage, with the strip being formed at intervals therealong with depressions extending transversely of the strip and dividing the latter into a plurality of sections each being connected to the next adjacent sections by readily tearable ligaments.
2. A vehicle as claimed in claim 1 wherein the strip is of oval or circular cross-section.
3. A vehicle as claimed in claim 1 where in the strip is of a form having two opposite and respectively concave and convex faces.
4. A vehicle as claimed in claim 1 with the strip being formed at intervals along one major surface thereof with ribs dividing the strip into plurality of sections.
5. A vehicle as claimed in claim 1 with the material of the vehicle being glyco-gelatine.
References Cited UNITED STATES PATENTS 2,068,703 1/1937 Powderrnaker '128-l55 X 2,764,501 9/1956 Perri 128--l56 X 3,249,109 5/1966 Maeth et a1 128268 ADELE M. EAGER, Primary Examiner.
U.S. Cl. X.R.
US549381A 1965-05-14 1966-05-11 Method and means for administering drugs Expired - Lifetime US3444858A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB20377/65A GB1142325A (en) 1965-05-14 1965-05-14 Means for administering drugs

Publications (1)

Publication Number Publication Date
US3444858A true US3444858A (en) 1969-05-20

Family

ID=10144947

Family Applications (1)

Application Number Title Priority Date Filing Date
US549381A Expired - Lifetime US3444858A (en) 1965-05-14 1966-05-11 Method and means for administering drugs

Country Status (2)

Country Link
US (1) US3444858A (en)
GB (1) GB1142325A (en)

Cited By (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3696811A (en) * 1971-06-17 1972-10-10 Squibb & Sons Inc Periodontal bandage and backing therefor
US3698392A (en) * 1971-04-21 1972-10-17 Kewanee Oil Co Topical dressing
US3731683A (en) * 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3797496A (en) * 1972-05-06 1974-03-19 Physio Medics Inc Post-extraction pads
US3960150A (en) * 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3972995A (en) * 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US3981303A (en) * 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
US3986510A (en) * 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3991760A (en) * 1975-12-02 1976-11-16 The Procter & Gamble Company Vaginal medicament dispensing means
US3993073A (en) * 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3993071A (en) * 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US3995633A (en) * 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US4020558A (en) * 1974-07-19 1977-05-03 Societe Sodermec Buccal implant for administering solubilizable products
DE2656387A1 (en) * 1975-12-15 1977-06-30 Hoffmann La Roche SOLID UNIVERSAL PHARMACEUTICAL DOSAGE FORM AS A DOSAGE FORM OF A DRUG, AND PROCESS AND SYSTEM FOR THEIR MANUFACTURING
US4039653A (en) * 1974-01-23 1977-08-02 Defoney, Brenman, Mayes & Baron Long-acting articles for oral delivery and process
US4292299A (en) * 1978-11-06 1981-09-29 Teijin Limited Slow-releasing medical preparation to be administered by adhering to a wet mucous surface
WO1982003174A1 (en) * 1981-03-19 1982-09-30 Haerle Anton Corpuscles containing drugs and use thereof in medecine and surgery
US4451260A (en) * 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
US4470962A (en) * 1979-08-14 1984-09-11 Key Pharmaceuticals, Inc. Polymeric diffusion matrix
US4482533A (en) * 1982-01-11 1984-11-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4529589A (en) * 1981-07-14 1985-07-16 Davydov Anatoly B Pharmaceutical composition for the treatment of diabetes mellitus
US4568536A (en) * 1985-02-08 1986-02-04 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
US4647448A (en) * 1984-06-22 1987-03-03 Smith Kline & French Laboratories Limited Pharmaceutical dosage unit
US4713239A (en) * 1979-05-29 1987-12-15 Vsesojuny Kardiologichesky Nauchny Tsentr Adkaemii Meditsinski Nauk Sssr Antianginal film and method of treating ischemic heart disease
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4842854A (en) * 1979-05-29 1989-06-27 Vsesojuzny Kardiologichesky Nauchny Tsentr Akademii Meditsinskiki Nauk Ssr Antianginal plate for treating ischemic heart disease
US4849246A (en) * 1985-10-09 1989-07-18 Wolfgang Schmidt Process for producing an administration or dosage form for drugs, reagents or other active ingredients
US4921695A (en) * 1979-05-29 1990-05-01 Babaian Eduard A Antianginal plate for treating ischemic heart disease
DE4217102A1 (en) * 1992-05-22 1993-11-25 Winand Neuhausen U-shaped mouth insert fitting between upper and lower teeth - releasing gas vapour or odour to mask or neutralise mouth odour
US5484602A (en) * 1985-05-01 1996-01-16 University Of Utah Research Foundation Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US6264974B1 (en) 1998-07-07 2001-07-24 Salvagnini Italia Spa Buccal and sublingual administration of physostigmine
USRE37382E1 (en) 1996-07-15 2001-09-18 Alayne Yates Gum pad for mucosal delivery of medication
US20010022964A1 (en) * 1998-09-25 2001-09-20 Leung Sau-Hung S. Fast dissolving orally consumable films
WO2002102296A1 (en) * 2001-06-15 2002-12-27 Schomakers Juergen Dosing stick containing rod-shaped tablets
US20030107149A1 (en) * 2001-10-12 2003-06-12 International Fluidics. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20030206942A1 (en) * 1998-09-25 2003-11-06 Neema Kulkarni Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent
US20030211136A1 (en) * 1998-09-25 2003-11-13 Neema Kulkarni Fast dissolving orally consumable films containing a sweetener
US20030219388A1 (en) * 2000-12-20 2003-11-27 Christian Kropf Remineralizing dental adhesive film
US6659442B1 (en) 1998-02-19 2003-12-09 Lts Lohamann Therapie-Systeme Ag Method and device for inserting a plurality of individual sheetlike forms of administration in a dispenser by forming a multilayer pile
US6682756B1 (en) 1996-12-16 2004-01-27 Lts Lohmann Therapie-Systeme Ag Individually dosed foil-form presentation which decomposes rapidly on contact with liquid and contains an active substance, in particular an aromatic substance
US20040122065A1 (en) * 2002-11-12 2004-06-24 Lerner E. Itzhak Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or buccally
US6800329B2 (en) * 1999-02-12 2004-10-05 Lts Lohmann Therapie-Systeme Ag Method for producing film-type dosage
US20040247648A1 (en) * 2003-05-02 2004-12-09 Fadden David John Fast dissolving orally consumable films containing a modified starch for improved heat and moisture resistance
US20040258896A1 (en) * 2001-10-12 2004-12-23 Monosolrx Llc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20050095363A1 (en) * 2002-01-25 2005-05-05 Detlev Neuland Method and device for producing products in web form
US20050109788A1 (en) * 2003-10-28 2005-05-26 Steven Catani Dispensing device for solid sweetener
US20050238591A1 (en) * 1997-06-06 2005-10-27 Sagel Paul A Tooth whitening substances
US20060039958A1 (en) * 2003-05-28 2006-02-23 Monosolrx, Llc. Multi-layer films having uniform content
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US20060147493A1 (en) * 2002-07-22 2006-07-06 Yang Robert K Packaging and dispensing of rapid dissolve dosage form
US20070122455A1 (en) * 2001-10-12 2007-05-31 Monosolrx, Llc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20070149731A1 (en) * 2001-10-12 2007-06-28 Monosolrx, Llc. PH modulated films for delivery of actives
US20070154527A1 (en) * 2001-10-12 2007-07-05 Monosoirx, Llc Topical film compositions for delivery of actives
US20070172515A1 (en) * 2006-01-20 2007-07-26 Monosolrx, Llc Film bandage for mucosal administration of actives
US20070186923A1 (en) * 2006-01-06 2007-08-16 Aceirx Pharmaceuticals, Inc. Drug storage and dispensing devices and systems comprising the same
US20070190157A1 (en) * 2006-01-20 2007-08-16 Monosoirx, Llc. Film lined packaging and method of making same
US20070281003A1 (en) * 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US20070293581A1 (en) * 2006-06-05 2007-12-20 Malcolm Hill Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies
US20070293582A1 (en) * 2006-06-05 2007-12-20 Malcolm Hill Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
US20080044454A1 (en) * 2002-04-11 2008-02-21 Monosolrx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20080075825A1 (en) * 2006-09-20 2008-03-27 Fuisz Richard C Edible Water-Soluble Film Containing a Foam Reducing Flavoring Agent
US20080081071A1 (en) * 2006-09-29 2008-04-03 Pradeep Sanghvi Film Embedded Packaging and Method of Making Same
US20080147044A1 (en) * 2006-01-06 2008-06-19 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US20080260809A1 (en) * 2002-04-11 2008-10-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20080268023A1 (en) * 2006-01-06 2008-10-30 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US20090048237A1 (en) * 2007-08-07 2009-02-19 Acelrx Pharmaceuticals, Inc. Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
DE102008023345A1 (en) 2008-05-13 2009-11-19 Lts Lohmann Therapie-Systeme Ag Film-like preparation with oily substances for oral administration
US20100021526A1 (en) * 2001-10-12 2010-01-28 Monosol Rx, Llc Ph modulated films for delivery of actives
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20100130551A1 (en) * 2008-11-21 2010-05-27 Acelrx Pharmaceuticals, Inc. Sufentanil Solid Dosage Forms Comprising Oxygen Scavengers and Methods of Using the Same
US20100137836A1 (en) * 2006-01-06 2010-06-03 Acelrx Pharmaceuticals, Inc. Storage and Dispensing Devices for Administration of Oral Transmucosal Dosage Forms
USRE42126E1 (en) 1999-07-02 2011-02-08 The Procter & Gamble Company Delivery system for oral care compositions comprising organosiloxane resins using a removable backing strip
US20110033541A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8548623B2 (en) 2009-03-18 2013-10-01 Acelrx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8865211B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8974826B2 (en) 2010-06-10 2015-03-10 Monosol Rx, Llc Nanoparticle film delivery systems
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US9265779B2 (en) 2008-05-13 2016-02-23 Lts Lohmann Therapie-Systeme Ag Method of using a film-shaped preparation comprising oily substances for oral administration
US9545376B2 (en) 2013-01-23 2017-01-17 Arx, Llc Production of unit dose constructs
US9554976B2 (en) 2002-09-11 2017-01-31 The Procter & Gamble Company Tooth whitening product
US10272607B2 (en) 2010-10-22 2019-04-30 Aquestive Therapeutics, Inc. Manufacturing of small film strips
US10285916B2 (en) 2012-10-17 2019-05-14 The Procter & Gamble Company Strip for the delivery of an oral care active and methods for applying oral care actives
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US11058856B2 (en) 2014-12-23 2021-07-13 Acelrx Pharmaceuticals, Inc. Systems, devices and methods for dispensing oral transmucosal dosage forms
US11077068B2 (en) 2001-10-12 2021-08-03 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11191737B2 (en) 2016-05-05 2021-12-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2133284A (en) * 1983-01-07 1984-07-25 English Grains Limited Resilient pharmaceutical unit for treating mouth ulcers
GB9101502D0 (en) * 1991-01-23 1991-03-06 Controlled Therapeutics Sct Controlled release compositions
US6136297A (en) * 1997-06-06 2000-10-24 The Procter & Gamble Company Delivery system for an oral care substance using a strip of material having low flexural stiffness
US6582708B1 (en) 2000-06-28 2003-06-24 The Procter & Gamble Company Tooth whitening substance
US5989569A (en) * 1997-06-06 1999-11-23 The Procter & Gamble Company Delivery system for a tooth whitener using a permanently deformable strip of material
US5879691A (en) * 1997-06-06 1999-03-09 The Procter & Gamble Company Delivery system for a tooth whitener using a strip of material having low flexural stiffness
US5894017A (en) * 1997-06-06 1999-04-13 The Procter & Gamble Company Delivery system for an oral care substance using a strip of material having low flexural stiffness
US6045811A (en) * 1997-06-06 2000-04-04 The Procter & Gamble Company Delivery system for an oral care substance using a permanently deformable strip of material
RU201716U1 (en) * 2020-08-18 2020-12-29 Гузэль Ярулловна Ибрагимова DEVICE FOR DETERMINING THE AMOUNT OF ADRENALINE AND ATROPINE FOR INTRAVENOUS ADMINISTRATION IN CARDIOPULMONARY RESIDUAL IN CHILDREN

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2068703A (en) * 1935-05-25 1937-01-26 Powdermaker Frank Bandage
US2764501A (en) * 1953-06-18 1956-09-25 Perri Myrtle Sangree Supply of pressure-sensitive reinforcements for paper and the like
US3249109A (en) * 1963-11-01 1966-05-03 Maeth Harry Topical dressing

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2068703A (en) * 1935-05-25 1937-01-26 Powdermaker Frank Bandage
US2764501A (en) * 1953-06-18 1956-09-25 Perri Myrtle Sangree Supply of pressure-sensitive reinforcements for paper and the like
US3249109A (en) * 1963-11-01 1966-05-03 Maeth Harry Topical dressing

Cited By (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) * 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3698392A (en) * 1971-04-21 1972-10-17 Kewanee Oil Co Topical dressing
US3731683A (en) * 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3696811A (en) * 1971-06-17 1972-10-10 Squibb & Sons Inc Periodontal bandage and backing therefor
US3960150A (en) * 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3981303A (en) * 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
US3986510A (en) * 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3993071A (en) * 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US3797496A (en) * 1972-05-06 1974-03-19 Physio Medics Inc Post-extraction pads
US4039653A (en) * 1974-01-23 1977-08-02 Defoney, Brenman, Mayes & Baron Long-acting articles for oral delivery and process
US4020558A (en) * 1974-07-19 1977-05-03 Societe Sodermec Buccal implant for administering solubilizable products
US3972995A (en) * 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US3991760A (en) * 1975-12-02 1976-11-16 The Procter & Gamble Company Vaginal medicament dispensing means
US3995633A (en) * 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
DE2656387A1 (en) * 1975-12-15 1977-06-30 Hoffmann La Roche SOLID UNIVERSAL PHARMACEUTICAL DOSAGE FORM AS A DOSAGE FORM OF A DRUG, AND PROCESS AND SYSTEM FOR THEIR MANUFACTURING
US4292299A (en) * 1978-11-06 1981-09-29 Teijin Limited Slow-releasing medical preparation to be administered by adhering to a wet mucous surface
US4713239A (en) * 1979-05-29 1987-12-15 Vsesojuny Kardiologichesky Nauchny Tsentr Adkaemii Meditsinski Nauk Sssr Antianginal film and method of treating ischemic heart disease
US4842854A (en) * 1979-05-29 1989-06-27 Vsesojuzny Kardiologichesky Nauchny Tsentr Akademii Meditsinskiki Nauk Ssr Antianginal plate for treating ischemic heart disease
US4921695A (en) * 1979-05-29 1990-05-01 Babaian Eduard A Antianginal plate for treating ischemic heart disease
US4470962A (en) * 1979-08-14 1984-09-11 Key Pharmaceuticals, Inc. Polymeric diffusion matrix
WO1982003174A1 (en) * 1981-03-19 1982-09-30 Haerle Anton Corpuscles containing drugs and use thereof in medecine and surgery
EP0157909A1 (en) * 1981-03-19 1985-10-16 MERCK PATENT GmbH Corpuscules containing medicaments
US4529589A (en) * 1981-07-14 1985-07-16 Davydov Anatoly B Pharmaceutical composition for the treatment of diabetes mellitus
US4482533A (en) * 1982-01-11 1984-11-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4451260A (en) * 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
US4647448A (en) * 1984-06-22 1987-03-03 Smith Kline & French Laboratories Limited Pharmaceutical dosage unit
US4568536A (en) * 1985-02-08 1986-02-04 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
US5484602A (en) * 1985-05-01 1996-01-16 University Of Utah Research Foundation Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US4849246A (en) * 1985-10-09 1989-07-18 Wolfgang Schmidt Process for producing an administration or dosage form for drugs, reagents or other active ingredients
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
DE4217102A1 (en) * 1992-05-22 1993-11-25 Winand Neuhausen U-shaped mouth insert fitting between upper and lower teeth - releasing gas vapour or odour to mask or neutralise mouth odour
USRE37382E1 (en) 1996-07-15 2001-09-18 Alayne Yates Gum pad for mucosal delivery of medication
US6682756B1 (en) 1996-12-16 2004-01-27 Lts Lohmann Therapie-Systeme Ag Individually dosed foil-form presentation which decomposes rapidly on contact with liquid and contains an active substance, in particular an aromatic substance
US20040137027A1 (en) * 1996-12-16 2004-07-15 Michael Horstmann Method for producing individually dosed active substance-containing and, in particular, aromatics-containing film-shaped administration forms rapidly disintegrating upon contact with liquid
US8883191B2 (en) 1996-12-16 2014-11-11 Lts Lohmann Therapie-Systeme Ag Method for producing individually dosed active substance-containing and, in particular, aromatics-containing film-shaped administration forms rapidly disintegrating upon contact with liquid
US20050238591A1 (en) * 1997-06-06 2005-10-27 Sagel Paul A Tooth whitening substances
US20080025927A1 (en) * 1997-06-06 2008-01-31 Sagel Paul A Delivery system for an oral care substance
US7175172B2 (en) * 1998-02-19 2007-02-13 Lts Lohmann Therapie-Systeme Ag Method and device for inserting a plurality of individual sheetlike forms of administration in a dispenser by forming a multilayer pile
US20040046305A1 (en) * 1998-02-19 2004-03-11 Lts Lohmann Therapie-Systeme Ag Method and device for inserting a plurality of individual sheetlike forms of administration in a dispenser by forming a multilayer pile
US6659442B1 (en) 1998-02-19 2003-12-09 Lts Lohamann Therapie-Systeme Ag Method and device for inserting a plurality of individual sheetlike forms of administration in a dispenser by forming a multilayer pile
US6264974B1 (en) 1998-07-07 2001-07-24 Salvagnini Italia Spa Buccal and sublingual administration of physostigmine
US20030206942A1 (en) * 1998-09-25 2003-11-06 Neema Kulkarni Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent
US7491406B2 (en) 1998-09-25 2009-02-17 Mcneil-Ppc, Inc. Fast dissolving orally consumable films
US20030211136A1 (en) * 1998-09-25 2003-11-13 Neema Kulkarni Fast dissolving orally consumable films containing a sweetener
US20040136922A1 (en) * 1998-09-25 2004-07-15 Leung Sau-Hung Spence Fast dissolving orally consumable films
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US7025983B2 (en) 1998-09-25 2006-04-11 Warner-Lambert Company Llc Fast dissolving orally consumable films
US20060039953A1 (en) * 1998-09-25 2006-02-23 Leung Sau-Hung S Fast dissolving orally consumable films
US6923981B2 (en) 1998-09-25 2005-08-02 Warner-Lambert Company Fast dissolving orally consumable films
US20080020024A1 (en) * 1998-09-25 2008-01-24 Neema Kulkarni Fast dissolving orally consumable films
US20050031675A1 (en) * 1998-09-25 2005-02-10 Sau-Hung Spence Leung Fast dissolving orally consumable film
US20010022964A1 (en) * 1998-09-25 2001-09-20 Leung Sau-Hung S. Fast dissolving orally consumable films
US7407669B2 (en) 1998-09-25 2008-08-05 Mcneil-Ppc, Inc. Fast dissolving orally consumable films
US6800329B2 (en) * 1999-02-12 2004-10-05 Lts Lohmann Therapie-Systeme Ag Method for producing film-type dosage
USRE42126E1 (en) 1999-07-02 2011-02-08 The Procter & Gamble Company Delivery system for oral care compositions comprising organosiloxane resins using a removable backing strip
US20060204559A1 (en) * 2000-03-23 2006-09-14 Bess William S Fast dissolving orally consumable films containing an ion exchange resin as a taste masking agent
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US7648712B2 (en) 2000-03-23 2010-01-19 Mcneil-Ppc, Inc. Fast dissolving orally consumable films containing a taste masking agent
US20030219388A1 (en) * 2000-12-20 2003-11-27 Christian Kropf Remineralizing dental adhesive film
US20040178218A1 (en) * 2001-06-15 2004-09-16 Jurgen Schomakers Dosing stick containing rod-shaped tablets
WO2002102296A1 (en) * 2001-06-15 2002-12-27 Schomakers Juergen Dosing stick containing rod-shaped tablets
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20070069416A1 (en) * 2001-10-12 2007-03-29 Monosolrx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20070122455A1 (en) * 2001-10-12 2007-05-31 Monosolrx, Llc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7910641B2 (en) 2001-10-12 2011-03-22 Monosol Rx, Llc PH modulated films for delivery of actives
US20070149731A1 (en) * 2001-10-12 2007-06-28 Monosolrx, Llc. PH modulated films for delivery of actives
US20070154527A1 (en) * 2001-10-12 2007-07-05 Monosoirx, Llc Topical film compositions for delivery of actives
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US11077068B2 (en) 2001-10-12 2021-08-03 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US10888499B2 (en) 2001-10-12 2021-01-12 Aquestive Therapeutics, Inc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20070281003A1 (en) * 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8685437B2 (en) 2001-10-12 2014-04-01 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US7824588B2 (en) 2001-10-12 2010-11-02 Monosol Rx, Llc Method of making self-supporting therapeutic active-containing film
US8652378B1 (en) 2001-10-12 2014-02-18 Monosol Rx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20050184427A1 (en) * 2001-10-12 2005-08-25 Monosolrx, Llc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20030107149A1 (en) * 2001-10-12 2003-06-12 International Fluidics. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US9931305B2 (en) 2001-10-12 2018-04-03 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US9855221B2 (en) 2001-10-12 2018-01-02 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20080260805A1 (en) * 2001-10-12 2008-10-23 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20100021526A1 (en) * 2001-10-12 2010-01-28 Monosol Rx, Llc Ph modulated films for delivery of actives
US20040258896A1 (en) * 2001-10-12 2004-12-23 Monosolrx Llc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8906277B2 (en) 2001-10-12 2014-12-09 Monosol Rx, Llc Process for manufacturing a resulting pharmaceutical film
US9108340B2 (en) 2001-10-12 2015-08-18 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20050095363A1 (en) * 2002-01-25 2005-05-05 Detlev Neuland Method and device for producing products in web form
US7232500B2 (en) 2002-01-25 2007-06-19 Lts Lohmann Therapie-Systeme Ag Method and device for producing products in web form
US20080260809A1 (en) * 2002-04-11 2008-10-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20080044454A1 (en) * 2002-04-11 2008-02-21 Monosolrx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US10111810B2 (en) 2002-04-11 2018-10-30 Aquestive Therapeutics, Inc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20060147493A1 (en) * 2002-07-22 2006-07-06 Yang Robert K Packaging and dispensing of rapid dissolve dosage form
US10493016B2 (en) 2002-09-11 2019-12-03 The Procter & Gamble Company Tooth whitening product
US9554976B2 (en) 2002-09-11 2017-01-31 The Procter & Gamble Company Tooth whitening product
US20040122065A1 (en) * 2002-11-12 2004-06-24 Lerner E. Itzhak Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or buccally
US20040247648A1 (en) * 2003-05-02 2004-12-09 Fadden David John Fast dissolving orally consumable films containing a modified starch for improved heat and moisture resistance
US20060039958A1 (en) * 2003-05-28 2006-02-23 Monosolrx, Llc. Multi-layer films having uniform content
US20050109788A1 (en) * 2003-10-28 2005-05-26 Steven Catani Dispensing device for solid sweetener
US20080268023A1 (en) * 2006-01-06 2008-10-30 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9642996B2 (en) 2006-01-06 2017-05-09 Acelrx Pharmaceuticals, Inc. Methods and apparatus for administering small volume oral transmucosal dosage forms
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US20070186923A1 (en) * 2006-01-06 2007-08-16 Aceirx Pharmaceuticals, Inc. Drug storage and dispensing devices and systems comprising the same
US10709881B2 (en) 2006-01-06 2020-07-14 Acelrx Pharmaceuticals, Inc. Apparatus for administering small volume oral transmucosal dosage forms
US10507180B2 (en) 2006-01-06 2019-12-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US10342762B2 (en) 2006-01-06 2019-07-09 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US10245228B2 (en) 2006-01-06 2019-04-02 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9744129B2 (en) 2006-01-06 2017-08-29 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8499966B2 (en) 2006-01-06 2013-08-06 Acelrx Pharmaceuticals, Inc. Method of moving a delivery member of a dispensing device for administration of oral transmucosal dosage forms
US8778393B2 (en) 2006-01-06 2014-07-15 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8778394B2 (en) 2006-01-06 2014-07-15 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8865211B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US20080147044A1 (en) * 2006-01-06 2008-06-19 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US20100137836A1 (en) * 2006-01-06 2010-06-03 Acelrx Pharmaceuticals, Inc. Storage and Dispensing Devices for Administration of Oral Transmucosal Dosage Forms
US9320710B2 (en) 2006-01-06 2016-04-26 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8905964B2 (en) 2006-01-06 2014-12-09 Acelrx Pharmaceuticals, Inc. Drug storage and dispensing devices and systems comprising the same
US20070172515A1 (en) * 2006-01-20 2007-07-26 Monosolrx, Llc Film bandage for mucosal administration of actives
US20070190157A1 (en) * 2006-01-20 2007-08-16 Monosoirx, Llc. Film lined packaging and method of making same
US20070293581A1 (en) * 2006-06-05 2007-12-20 Malcolm Hill Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies
US20070293580A1 (en) * 2006-06-05 2007-12-20 Malcolm Hill Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies
US20070293582A1 (en) * 2006-06-05 2007-12-20 Malcolm Hill Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
US20080075825A1 (en) * 2006-09-20 2008-03-27 Fuisz Richard C Edible Water-Soluble Film Containing a Foam Reducing Flavoring Agent
US7972618B2 (en) 2006-09-20 2011-07-05 Monosol Rx, Llc Edible water-soluble film containing a foam reducing flavoring agent
US20080081071A1 (en) * 2006-09-29 2008-04-03 Pradeep Sanghvi Film Embedded Packaging and Method of Making Same
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US20090048237A1 (en) * 2007-08-07 2009-02-19 Acelrx Pharmaceuticals, Inc. Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
DE102008023345A1 (en) 2008-05-13 2009-11-19 Lts Lohmann Therapie-Systeme Ag Film-like preparation with oily substances for oral administration
US8758803B2 (en) 2008-05-13 2014-06-24 Lts Lohmann Therapie-Systeme Ag Film-shaped preparation comprising oily substances for oral administration
US9265779B2 (en) 2008-05-13 2016-02-23 Lts Lohmann Therapie-Systeme Ag Method of using a film-shaped preparation comprising oily substances for oral administration
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US20100130551A1 (en) * 2008-11-21 2010-05-27 Acelrx Pharmaceuticals, Inc. Sufentanil Solid Dosage Forms Comprising Oxygen Scavengers and Methods of Using the Same
US8574189B2 (en) 2009-03-18 2013-11-05 Acelrx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US11676691B2 (en) 2009-03-18 2023-06-13 Vertical Pharmaceuticals, Llc Storage and dispensing devices for administration of oral transmucosal dosage forms
US8548623B2 (en) 2009-03-18 2013-10-01 Acelrx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US10896751B2 (en) 2009-03-18 2021-01-19 Acelrx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US10821074B2 (en) 2009-08-07 2020-11-03 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US10034833B2 (en) 2009-08-07 2018-07-31 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US9687454B2 (en) 2009-08-07 2017-06-27 Indivior Uk Limited Sublingual and buccal film compositions
US11135216B2 (en) 2009-08-07 2021-10-05 Indivior Uk Limited Sublingual and buccal film compositions
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US20110033541A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
US8974826B2 (en) 2010-06-10 2015-03-10 Monosol Rx, Llc Nanoparticle film delivery systems
US10940626B2 (en) 2010-10-22 2021-03-09 Aquestive Therapeutics, Inc. Manufacturing of small film strips
US10272607B2 (en) 2010-10-22 2019-04-30 Aquestive Therapeutics, Inc. Manufacturing of small film strips
US10285915B2 (en) 2012-10-17 2019-05-14 The Procter & Gamble Company Strip for the delivery of an oral care active and methods for applying oral care actives
US10285916B2 (en) 2012-10-17 2019-05-14 The Procter & Gamble Company Strip for the delivery of an oral care active and methods for applying oral care actives
US9545376B2 (en) 2013-01-23 2017-01-17 Arx, Llc Production of unit dose constructs
US9662297B2 (en) 2013-01-23 2017-05-30 Arx, Llc Production of unit dose constructs
US9814674B2 (en) 2013-01-23 2017-11-14 Arx, Llc Production of unit dose constructs
US9662301B2 (en) 2013-01-23 2017-05-30 Arx, Llc Production of unit dose constructs
US11058856B2 (en) 2014-12-23 2021-07-13 Acelrx Pharmaceuticals, Inc. Systems, devices and methods for dispensing oral transmucosal dosage forms
US11191737B2 (en) 2016-05-05 2021-12-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation

Also Published As

Publication number Publication date
GB1142325A (en) 1969-02-05

Similar Documents

Publication Publication Date Title
US3444858A (en) Method and means for administering drugs
US3429308A (en) Method for administering drugs from a vehicle adhering by suction to the parabuccal cavity mucous membrane
US3887699A (en) Biodegradable polymeric article for dispensing drugs
US4317447A (en) Drug delivery system
US5139790A (en) Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5004601A (en) Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US3656483A (en) Intrauterine medicator
US5244668A (en) Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US4020558A (en) Buccal implant for administering solubilizable products
US3880991A (en) Polymeric article for dispensing drugs
EP0174108B1 (en) Transdermal delivery devices
ATE66142T1 (en) PHARMACEUTICAL AND DOSAGE FORM FOR MEDICINAL INGREDIENTS, REAGENTS OR THE LIKE AND PROCESS FOR THEIR MANUFACTURE.
US4585451A (en) Devices which are adapted to slowly release chemicals, such as hormones, drugs and minerals
EP0862396A1 (en) Intravaginal rings with insertable drug-containing core
EP0200490A3 (en) Compositions for noninvasive administration of sedatives, analgesics, and anesthetics
ES488168A0 (en) PROCESS FOR THE PREPARATION OF PHARMACEUTICAL OR MEDICINAL TABLETS FOR ORAL ADMINISTRATION, WITH DELAYED DELIVERY OF ACTIVE ACTIVE, IN TABLETS IN WHICH THE QUANTITY OF RELEASE OF THE ACTIVE AGENT IS DEFAULT.
WO1998004220A9 (en) Intravaginal rings with insertable drug-containing core
US3415249A (en) Suppository
EP0021758B1 (en) Veterinary preparations for ruminant animals
Roy et al. Long-term reversible contraception with levonorgestrel-releasing Silastic rods
US2857914A (en) Means for administering medicines
HUT53816A (en) Method for elaborating therapeutical system feeding the agent gradually through the skin
EP0035531A4 (en) Polymeric drug delivery applicators.
US2333342A (en) Suppository
KR830001816B1 (en) Method for producing polymerized diffusive matrix